Biotech | January 07, 2022
Lilly and Entos collaborate for therapies in multiple neurologic indications
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
It has also been granted permission to conduct trials for booster dose
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Medical footprint expansion with deeper medical grade skin contact material science expertise
Effectiveness of Covaxin against the Omicron variant is currently being studied
After specialising in laparoscopy, proctology, urology, and cosmetic surgeries, Glamyo Health is now venturing into orthopaedic surgeries
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Subscribe To Our Newsletter & Stay Updated
